MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'bms'. Sat, 03 Sep 2011 02:03:06 +0100 http://www.medworm.com/index.php?rid=4852861&cid=t_131164_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fburning-mouth-syndrome-may-be-cured-with-magnesium-supplements%2F2011.05.22 Patients with burning mouth syndrome (BMS) have two major findings: one, burning sensations in their mouth and two, no anatomical changes present in their mouth to relate to this burning. Dr. Henkin and colleagues at the Center for Molecular Nutrition and Sensory Disorders have clinically distinguished two major groups of patients with BMS. One group has burning limited only to their tongue – called GLOSSOPYROSIS. The other group has burning in their entire mouth, including their tongue, lips, palette, gums and pharynx – called OROPYROSIS. They have recently been able to distinguish these two patient groups biochemically. Patients with GLOSSOPYROSIS have lower levels of magnesium in their red blood cells (erythrocytes) than do patients with OROPYROSIS or normal subjects. (more…) ... Better Health blogs http://www.medworm.com/rss/comments.php?id=4852861 Sun, 22 May 2011 19:00:00 +0100 4852861 http://www.medworm.com/index.php?rid=4828965&cid=t_131164_107_f&fid=36672&url=http%3A%2F%2Fwww.sciencebase.com%2Fscience-blog%2Flatest-science-news-with-a-spectral-twist.html Romantic notes – Cassis base 345B, undecavertol, 1,3-oxathiane oxane, isospirene… Perfume can be so romantic! But the chemical components underpinning the often-enticing and seductive smells of fragrances are, one might say equal parts art and science. One of the most intriguing elements of several fragrances, including popular perfumes like Le monde est beau by Daniela Andrier and DKNY Be Delicious by Maurice Roucel is the fruity top note – blackcurrant. Socioeconomic pollutants – How much socioeconomic factors affect exposure to persistent organic pollutants, especially during vulnerable periods of life such as pregnancy and childhood, is not yet well understood. A new study has investigated the relationship between maternal social class, based on occupation type,... Sciencebase Science Blog blogs http://www.medworm.com/rss/comments.php?id=4828965 Mon, 16 May 2011 07:40:50 +0100 4828965 http://www.medworm.com/index.php?rid=4636621&cid=t_131164_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F03%2F25%2Ftherapeutic-response-to-the-angiogenesis-inhibitor-sunitinib-in-ovarian-clear-cell-cancer%2F A group of international researchers reported sustained responses in two ovarian clear cell cancer (OCCC) patients with chemotherapy-resistant disease, who were treated with the anti-angiogenesis inhibitor sunitinib (Sutent®). The researchers emphasize the growing realization that OCCC is molecularly and clinically distinct as compared to other forms of ovarian cancer, and note significant common scientific characteristics [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4636621 Fri, 25 Mar 2011 22:57:20 +0100 4636621 http://www.medworm.com/index.php?rid=3929410&cid=t_131164_131_f&fid=35743&url=http%3A%2F%2Fthegenesherpa.blogspot.com%2F2010%2F08%2Fplavix-and-2c19-brewhahhah.html Yes,I am a little slow Yes,It has been a long time. But,I am back. With a serious hankering to smash some studies. I already pooh pooh'd the Migraine SNP study on Twitter, but the Plavix stuff.....That deserves a blogpost. To quote a famous caridologist and friend "If Plavix really didn't work for 30% of patients, why don't we see more in-stent thrombosis?" Translation: Your science is nice, but how does it fly in the real world? I have to tell you, at first I couldn't answer. It was a great question. Do a full third of people have that severe failure? The obvious answer is NO. If 1/3 rethrombosed, we wouldn't be using Drug Eluting Stents.So what is the answer:Apparently a BMS (I.E. Plavix maker) funded study investigated thisWe hypothesized that the benefits of clopidogrel as compared wit... Gene Sherpas: Personalized Medicine and You blogs http://www.medworm.com/rss/comments.php?id=3929410 Tue, 31 Aug 2010 23:46:00 +0100 3929410 http://www.medworm.com/index.php?rid=3718646&cid=t_131164_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F07%2F01%2Fbms-345541-dasatinib-resensitizes-carboplatin-resistant-recurrent-ovarian-cancer-cells%2F Johns Hopkins medical researchers discovered through proteomic analysis that RELA and STAT5 are upregulated in carboplatin resistant ovarian cancer cells, according to a published study appearing in the June 18 edition of PLoS One. Moreover, the researchers also demonstrated that BMS-345541 (a NF-kappaB inhibitor) and dasatinib (a STAT5 inhibitor) could resensitize carboplatin-resistant, recurrent ovarian cancer [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3718646 Fri, 02 Jul 2010 02:53:34 +0100 3718646 http://www.medworm.com/index.php?rid=2862485&cid=t_131164_88_f&fid=38956&url=http%3A%2F%2Fallbleedingstops.blogspot.com%2F2009%2F10%2Fdifferential-schmifferential.html This study has since been validated in a multicenter study done in the era of widespread Pneumococcal-vaccine use.Certainly there are many reasons for admitting a child at low risk (BMS = 0) of bacterial meningitis: vomiting, intractable pain, lack of appropriate follow-up, or lack of an appropriate (or sufficiently reassured) caregiver. However in many instances the BMS can be a useful tool in changing your disposition from "slam-dunk admit" to "home to rest and recover."References:Development and Validation of a Multivariable Predictive Model to Distinguish Bacterial From Aseptic Meningitis in Children in the Post-Haemophilus influenzae Era. PEDIATRICS Vol. 110 No. 4 October 2002, pp. 712-719Clinical Prediction Rule for Identifying Children With Cerebrospinal Fluid Pleocytosis at Very Lo... Movin' Meat blogs http://www.medworm.com/rss/comments.php?id=2862485 Mon, 05 Oct 2009 04:11:00 +0100 2862485 http://www.medworm.com/index.php?rid=2660940&cid=t_131164_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2009%2F08%2F01%2Fbms-817378%2F A comments to BMS-777607 suggest that this structure is the backup: WO/2009/094427 Posted in BMS, c-Met (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=2660940 Sat, 01 Aug 2009 11:53:47 +0100 2660940 http://www.medworm.com/index.php?rid=2649196&cid=t_131164_131_f&fid=35743&url=http%3A%2F%2Fthegenesherpa.blogspot.com%2F2009%2F07%2Fpharmacogenetic-indication-for.html That's one way to market the newest medication to prevent stroke, heart attack or stent thrombosis. Wha? Yes, I mean, Prasugrel otherwise known as Effient is FDA approved for use in these patients. But one thing I was thinking is that, since the FDA put on the insert of Plavix that 2C19 testing may be useful to identify people who will not respond to Plavix (generic Clopidogrel)Perhaps, the marketing geniuses over at Eli Lilly could use this as an FDA suggestion that these 2C19 people may be better off with Prasugrel. Yes, it would be one of the most brilliant ways to market pharmacogenomics. I can only imagine the DTC genomics companies salivating over this "We offer the 2C19, test. Act now, save your life." Technically, It actually could. Yes, all the stops would be pulled out and it co... Gene Sherpas: Personalized Medicine and You blogs http://www.medworm.com/rss/comments.php?id=2649196 Wed, 29 Jul 2009 12:01:00 +0100 2649196 http://www.medworm.com/index.php?rid=2424496&cid=t_131164_150_f&fid=34889&url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2009%2F05%2Fbehrman-wasnt-first-patient.html Andy Behrman -- aka "Electroboy" -- is being raked over the coals for first shilling for BMS' drug Abilify (for which BMS paid him $400,000), then "shaking down" BMS for a new contract and then launching an anti-Abilify campaign when he didn't get it (see "Andy Behrman, Now an Anti-BMS Spokesperson, Says 'Ask Your Doctor If Abilify is Wrong for You'").While many bloggers are focused on what Behrman has been and is doing, few are focused on what I consider to be the real issues:* Is it appropriate for pharma companies to pay patients such huge sums to promote their products?* Is this done often by all pharmaceutical companies or is it just something unique to BMS?To answer these questions, I will relate a personal story where I was involved with another patient paid huge sums of money by BM... Pharma Marketing Blog blogs http://www.medworm.com/rss/comments.php?id=2424496 Wed, 20 May 2009 11:32:00 +0100 2424496 http://www.medworm.com/index.php?rid=2417159&cid=t_131164_150_f&fid=34889&url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2009%2F05%2Fandy-behrman-now-anti-bms-spokesperson.html The saga of the Andy Behrman, the patient that Bristol-Myers Squibb (BMS) paid hundreds of thousands of dollars (but balked at paying him millions) to help promote its drug Abilify, continues.Jim Edwards of BNET Pharma reports that Behrman has resorted to an e-mail campaign that Edwards says is a "long plug" for Behrman's new book (see "Andy Behrman Resorts to Spam in Fight vs. BMS and Abilify").In reading Behrman's e-mail message I found a link to a 60-second anti-Abilify video ad he posted to YouTube ("Abilify Kills"; see below). This "anti-ad" lists several of the side effects of Abilify and finishes with a twist on the famous "Ask Your Doctor" closing found in all DTC Rx drug ads: "Ask your doctor if Abilify is wrong for you."Now that Mr. Behrman is getting so much media attention and ... Pharma Marketing Blog blogs http://www.medworm.com/rss/comments.php?id=2417159 Tue, 19 May 2009 11:16:00 +0100 2417159 http://www.medworm.com/index.php?rid=2405420&cid=t_131164_109_f&fid=34750&url=http%3A%2F%2Fpsychcentral.com%2Fblog%2Farchives%2F2009%2F05%2F11%2Fhiding-akathisia-in-abilify%2F What if your new drug has an unwanted side effect that’s going to impact sales if it becomes widely known? Well, in the case of Abilify (aripiprazole) apparently, you make that side effect’s data difficult to find (or just fail to report it when it’s ugly). CL Psych has the scoop: The authors go through a long list of second-generation antipsychotic medications. The drug that receives the least attention is aripiprazole (Abilify). The authors conclude that “in studies comparing aripiprazole with placebo, akathisia rates in the aripiprazole arm were similar in some studies, and higher in others. As with other SGAs, akathisia rates with aripiprazole were lower than those of FGAs.” So Abilify causes less akathisia than older medications and it’s unclear ... World of Psychology blogs http://www.medworm.com/rss/comments.php?id=2405420 Mon, 11 May 2009 20:29:27 +0100 2405420 http://www.medworm.com/index.php?rid=2349168&cid=t_131164_129_f&fid=36038&url=http%3A%2F%2Fwww.everydayhealth.com%2Fblog%2Ftrevis-life-with-multiple-sclerosis-ms%2Fms-progression-what-does-it-all-mean%2F Last week several of you commented on our post about recovery.  Therefore, I thought this might be a good time to talk about multiple sclerosis progression. RRMS, SPMS, PPMS, RPMS, WMS, BMS… what does it all mean? Those letters mean something to most of us with MS but what do they mean outside of the clinic in the real world? Just to make sure we’re all on the same page, they stand for (in order) relapsing-remitting, secondary-progressive, primary-progressive, relapsing-progressive, worsening and benign multiple sclerosis respectively. Never heard of some of those?  Well, 40 years ago you wouldn’t have heard any of them! The first three were developed to group our disease activity for clinical trials of the first MS drugs.  In order to see how the drugs reacted to disease “categ... Life with MS blogs http://www.medworm.com/rss/comments.php?id=2349168 Mon, 20 Apr 2009 18:40:36 +0100 2349168 http://www.medworm.com/index.php?rid=2300956&cid=t_131164_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2009%2F03%2F26%2Fbms-777607%2F BMS homegrown Ph1 c-Met / AXL / Ron Inhibitor.  As of now PDB 3F82 has not yet been released. The N-Oxide is a major metabolite, and from the trial notes its either toxic, potent, or prevalent… The J Med Chem doesn’t mention it. Posted in BMS, c-Met (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=2300956 Fri, 27 Mar 2009 03:38:12 +0100 2300956 http://www.medworm.com/index.php?rid=2182583&cid=t_131164_150_f&fid=34889&url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2009%2F02%2Fbmss-oh-yes-i-can-ad-is-reminescent-of.html (Source: Pharma Marketing Blog) Pharma Marketing Blog blogs http://www.medworm.com/rss/comments.php?id=2182583 Fri, 13 Feb 2009 12:01:00 +0100 2182583 http://www.medworm.com/index.php?rid=2147559&cid=t_131164_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2009%2F01%2Flilly-daiichi-sankyo-effient-clot-wars.html Back stories here. And here.Food and Drug Administration medical reviewers said the agency should approve Effient (prasugrel), a proposed anti-clotting drug being developed by Eli Lilly and Co. and Daiichi Sankyo Co., but should carry tough warnings about bleeding and cancer risks.Reviews of Prasugrel by different FDA divisions were posted on the agency's Web site Friday.The drug faces a review Tuesday by medical experts who serve on the agency's cardiovascular and renal drugs advisory committee. The panel is being asked to recommend if prasugrel should be approved for use in certain patients at risk for a heart attack and, if so, what warnings should be placed on the drug.Last month, a European Medicines Agency committee issued a positive opinion recommending approval of prasugrel. That o... PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=2147559 Fri, 30 Jan 2009 16:50:00 +0100 2147559 http://www.medworm.com/index.php?rid=2141594&cid=t_131164_131_f&fid=35743&url=http%3A%2F%2Fthegenesherpa.blogspot.com%2F2009%2F01%2Fplavix-plavix-plavix.html I just finished up giving a Yale Affiliated Hospitals Lecture to a bunch of residents on the topic of pharmacogenomics. Not to toot my own horn, but several residents came up to me and asked......"Why didn't I learn this in medical school?" Even better was the 3rd year medical students who just finished up Pharmacology last year....they said "The EXACT SAME THING".......Ok, so here's my beef. Why in the hell aren't we teaching this in medical school. I know I have said this before......but what in the hell is going on here? We have data and not just data , but DAMN GOOD data....and instead we are still pumping JakStat pathways down the throats of our second year medical students.....I have a very big problem here and I need it fixed. Why can't we get physicians who study PgX to teach this?... Gene Sherpas: Personalized Medicine and You blogs http://www.medworm.com/rss/comments.php?id=2141594 Wed, 28 Jan 2009 16:29:00 +0100 2141594 http://www.medworm.com/index.php?rid=1853587&cid=t_131164_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F10%2Flilly-beat-bms-to-imclone.html ImClone has agreed to be acquired by Eli Lilly for about $6.1 billion, Reuters reports, citing sources familiar with the situation.More (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1853587 Mon, 06 Oct 2008 09:19:00 +0100 1853587 http://www.medworm.com/index.php?rid=1785903&cid=t_131164_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F09%2Fare-astrazeneca-mystery-bidder-for.html You tell me. (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1785903 Fri, 12 Sep 2008 07:50:00 +0100 1785903 http://www.medworm.com/index.php?rid=1664246&cid=t_131164_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F07%2Fgeneric-german-plavix-ja.html A German court has allowed a generic version of the blockbuster anticlotting drug Plavix to be marketed there (starting immediately) by Ratiopharm and another generic-drug company called Yes.WSJ (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1664246 Wed, 30 Jul 2008 05:55:00 +0100 1664246 http://www.medworm.com/index.php?rid=1652319&cid=t_131164_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F07%2Fplatelet-wars-plavix-vs-effient.html The chief operating officer of Bristol-Myers Squibb said Eli Lilly's rival Effient blood clot preventer will be a "niche" product if approved and the TRITON study found it either harmed or offered no benefit to three types of patients."There are three important subgroups of patients that seem to derive either net harm or no clinical advantages" from Effient, Lamberto Andreotti told analysts in a conference call.More (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1652319 Thu, 24 Jul 2008 19:29:00 +0100 1652319 http://www.medworm.com/index.php?rid=1552971&cid=t_131164_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F06%2Fwill-bms-and-az-get-saxagliptin-blues.html aka Onglyza!The Food and Drug Administration is considering tougher standards for new and current diabetes drugs, raising concern in the pharmaceutical industry that the agency may ultimately raise the time and cost needed to approve of a wide array of new drugs.The FDA is weighing whether to insist that new diabetes drugs have a positive impact on cardiovascular disease and life span, which are more difficult to measure than current benchmarks such as lower blood sugar.WSJ (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1552971 Sat, 28 Jun 2008 19:16:00 +0100 1552971 http://www.medworm.com/index.php?rid=1472467&cid=t_131164_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2008%2F05%2Fplavix-aspirin-combo-application-pulled.html European regulators have revealed that Sanofi-Aventis and Bristol-Myers Squibb have withdrawn a marketing authorisation application for a drug which combines the blockbuster Plavix with aspirin.The European Medicines Agency said it had been formally notified by the firms’ decision to withdraw its application for DuoPlavin (clopidogrel/acetylsalicylic acid), which was expected to be used by patients already taking clopidogrel (Plavix) and acetylsalicylic acid (aspirin) for the prevention of atherothrombotic events in acute coronary syndrome. The application was submitted to the EMEA on May 30 and was under review by the agency's Committee for Medicinal Products for Human Use (CHMP).More (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=1472467 Wed, 28 May 2008 10:56:00 +0100 1472467 http://www.medworm.com/index.php?rid=1090660&cid=t_131164_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1408  Didn’t want to be flip within the body of that last post, as the situation is anything but funny and it’s not really any one person’s fault (and not this individual’s). But  now, a brief moment with a sponsor of BMS’ Productivity Transformation Initiative, courtesy of OfficeMax.  (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1090660 Wed, 12 Dec 2007 18:10:34 +0100 1090660 http://www.medworm.com/index.php?rid=1090661&cid=t_131164_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1407 Sadly, this year will bring bad news, in the form of pink slips, for thousands of U.S. workers in a number of industries, as The Guardian recently reported (Click here for a sobering update).  BMS leads the pharma pack just now.  Local newspapers report that the company’s 10% in planned staff reductions will not affect anyone at [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1090661 Wed, 12 Dec 2007 18:08:43 +0100 1090661 http://www.medworm.com/index.php?rid=1051232&cid=t_131164_109_f&fid=34800&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FClinicalPsychologyAndPsychiatryACloserLook%2F%7E3%2F190750786%2Fwill-antipsychotic-coverup-continue.html At this point, there are a slew of lawsuits facing manufacturers of atypical antipsychotics, from individual suits ranging to suits brought by state governments. Allegations of fraudulent marketing, kickbacks, and hiding research results are among the claims made in such suits. For example, Arkansas recently filed a lawsuit. Read it here and read my take here. The most important thing that could come from these suits in the long run is not the money that various drug companies may have to shell out in fines. No, the important piece is the information, the internal documents that I am nearly certain document numerous instances demonstrating bad science, covering up negative data, and detailing ludicrous marketing campaigns. Check out the documents on Zyprexa over at Furious Seasons and you'... Clinical Psychology and Psychiatry: A Closer Look blogs http://www.medworm.com/rss/comments.php?id=1051232 Mon, 26 Nov 2007 15:08:00 +0100 1051232 http://www.medworm.com/index.php?rid=979410&cid=t_131164_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1351 GSK just announced today that it would be eliminating 900 jobs at its facility in Cidra, Puerto Rico. More from the International Herald Tribune.  But Pharmalot reports that BMS will be announcing major cuts in December. Unfortunately, it is far from the only pharma or bio company in job-cutting mode. Pharmalot, In the Pipeline and FierceBiotech  each offered [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=979410 Thu, 25 Oct 2007 17:22:17 +0100 979410 http://www.medworm.com/index.php?rid=944562&cid=t_131164_150_f&fid=34889&url=http%3A%2F%2Fpharmamkting.blogspot.com%2F2007%2F10%2Fstatins-and-heart-disease-look-behind.html I noticed that Ed Silverman picked up on a statin study published in the New England Journal of Medicine (NEJM) that suggests statins such as Pravachol -- the drug used in the study -- help prevent heart attacks for at least a decade after people stop taking them.This caught my attention because I recently stopped taking Pravachol, a Bristol-Myers Squibb (BMS) product, after about 12 years because I started getting leg cramps at night. Since I stopped, no cramps. I wondered if my risk for heart attack would increase because I stopped taking the drug, so I was pleasantly surprised to read this story, especially because it was about Pravachol. [BTW, I will discuss this with my cardiologist on Tuesday.]The problem is, if I had just read the headlines and skimmed Ed's summary, I may have misse... Pharma Marketing Blog blogs http://www.medworm.com/rss/comments.php?id=944562 Thu, 11 Oct 2007 12:11:00 +0100 944562 http://www.medworm.com/index.php?rid=815350&cid=t_131164_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2007%2F08%2F21%2Fmore-her%2F ‘nother ErbB 1,2,4 crystal forms app from BMS in US20070191375: … (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=815350 Wed, 22 Aug 2007 03:04:48 +0100 815350 http://www.medworm.com/index.php?rid=769226&cid=t_131164_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1295 I hate posting news like this. BMS plans to cut staff later this year, mainly in “back office” and “infrastructure” positions (translation: IT, manufacturing and operations?) More from CNN But this morning, Bloomberg reports that J&J also plans to reduce its workforce by 4% this year.  More from this morning’s news.  AstraZeneca announced 11% job cuts last week. (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=769226 Tue, 31 Jul 2007 12:25:44 +0100 769226 http://www.medworm.com/index.php?rid=758659&cid=t_131164_109_f&fid=34800&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FClinicalPsychologyAndPsychiatryACloserLook%2F%7E3%2F137441398%2Fbristol-myers-squibb-childrens-hospital.html There really is a hospital named after a drug company. I'd write more, but Roy Poses at Health Care Renewal has it covered. Are you kidding me? (Source: Clinical Psychology and Psychiatry: A Closer Look) Clinical Psychology and Psychiatry: A Closer Look blogs http://www.medworm.com/rss/comments.php?id=758659 Thu, 26 Jul 2007 02:08:00 +0100 758659 http://www.medworm.com/index.php?rid=742590&cid=t_131164_109_f&fid=34800&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FClinicalPsychologyAndPsychiatryACloserLook%2F%7E3%2F134948506%2Fabilify-its-tricky-to-rock-fda.html In the "you're kidding me" category, we have a report from Forbes that Abilify (aripiprazole) is going to be going up for FDA priority review as a depression treatment. I was able to track down exactly one placebo-controlled study using this drug as an antidepressant. Participants who did not show satisfactory response to an antidepressant trial were assigned to receive either Abilify or a placebo in addition to their antidepressant. As you'll see, this was a study worthy of close examination.Study Results. I read the study results and was underwhelmed. The authors (via their ghostwriter(s) to some unknown extent) reported that the difference between those receiving add-on Abilify vs. add-on placebo was three points on the Montgomery-Asberg Depression Rating Scale (MADRS). For perspective,... Clinical Psychology and Psychiatry: A Closer Look blogs http://www.medworm.com/rss/comments.php?id=742590 Wed, 18 Jul 2007 13:47:00 +0100 742590 http://www.medworm.com/index.php?rid=740607&cid=t_131164_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1258 The Leadership Sphere blog just reviewed the classic business book “Good to Great,” with some insights on leaders and one pharma industry leader in particular.  The best leaders combine personal humility with intense professional will and resolve.  Read the entire post, excerpted below: They set up successors for success, make sure that those who follow them [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=740607 Tue, 17 Jul 2007 18:04:19 +0100 740607 http://www.medworm.com/index.php?rid=728724&cid=t_131164_150_f&fid=35781&url=http%3A%2F%2Fwww.qdinformation.com%2Fqdisblog%2F2007%2F03%2F28%2Fmore-on-sanofi-aventis-bristol-myers-squibb-potential-mergersanofi-board-split-over-54bn-deal-to-acquire-bristol-myers-business-industry-sectors-health-timesonline%2F Seems the Sanofi BMS merger talks haven’t been without some truth to them. Now the Times Online is reporting that there is a split on the Sanofi side over strategy Sanofi board split over $54bn deal to acquire Bristol-Myers-Business-Industry Sectors-Health-TimesOnline The Times has learnt that a disagreement over strategy has emerged between Jean-François Dehecq, the Sanofi chairman, who favours a transformational deal with BMS, and Gérard Le Fur, his younger chief executive, who has emphasised the need to focus on the group’s internal drug research and development programme. The article goes on to say that the former view of merger with transformation is more probable. I think that it might be the less attractive strategy in the long run. I’m not a big fan of mergers sin... QDIS Blog blogs http://www.medworm.com/rss/comments.php?id=728724 Thu, 29 Mar 2007 01:09:38 +0100 728724